SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Mixed oncology-trial results are driving attention: traders cite BioNTechs BNT113 setback and modest breast-cancer benefit, while bulls point to other promising pipeline readouts and upcoming updates. Debate also reflects concern over the leadership transition and the time needed to turn the pipeline into commercial products.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios quarterly results beat expectations and lifted its full-year outlook, but a softer next-quarter organic growth forecast signaled deceleration and drove a sharp selloff. Traders are debating whether slowing messaging growth and weaker customer expansion outweigh the strong results, while some see the pullback as a potential bounce opportunity.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention as traders discuss a shift from volatile technology and growth stocks toward dividend-paying value and defensive holdings amid market uncertainty. Many point to its recent strength and keep accumulating, while others question its yield and warn that rising Treasury yields or a return to tech could weigh on the fund.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Traders are focused on whether Q3 results will show that oral Wegovy demand and international expansion can offset concerns about Eli Lillys competitive lead in GLP-1 drugs. The community is divided: some see the pill rollout and low valuation as recovery potential, while others remain cautious about Novos execution, management and pipeline; the Hengrui licensing deal also drew debate as a longer-term pipeline move.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A sharp breakout to a fresh 52-week high has put TGTX in focus, with traders pointing to BRIUMVIs commercial growth and anticipation of earnings and upcoming subcutaneous data. Buyout and short-squeeze theories are circulating, but remain speculation; others see the rally as momentum ahead of those catalysts.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvanas Q3 report, with record sales and revenue growth but an EPS miss and weaker margins, sparked a sharp rally and renewed short-squeeze speculation; traders are also citing the SECs decision to close its investigation without recommending enforcement. The move has drawn competing views, with bulls focused on growth and squeeze potential while bears question profitability, guidance and valuation.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

A sharp selloff and persistent volatility dominate discussion, with traders pointing to broader weakness in miners and uncertainty over Sangdongs production ramp and near-term cash flows. Some remain bullish on tungsten-market fundamentals and the mines first shipment, while others say the investor-day discussion offered little new detail and are concerned about execution.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings, supported by growth in Dupixent and Eylea HD, sparked a sharp share-price surge and a new 52-week high. Traders are broadly bullish on the breakout, while debating whether the move can hold or will retrace.

Crown Castle, Inc. engages in the business of owning, operating, and leasing shared communications infrastructure. It operates through the following segments: Towers, Fiber, and Other. The Towers segment focuses on providing coverage and capacity for wireless carrier network deployments. The Fiber segment includes communications infrastructure offerings of small cells and fiber solutions. The Other segment is involved in corporate assets such as cash and cash equivalents. The company was founded by Ted B. Miller Jr. and Edward C. Hutcheson Jr. in 1994 and is headquartered in Houston, TX.

Crown Castle Inc

Crown Castle International Corp

Reports that SpaceX is in talks to access at least 80,000 U.S. cell sites, including Crown Castles towers, have focused attention on the prospect of a major new leasing customer. Traders see potential tower revenue upside, while skeptics note that no agreement is signed and question whether SpaceXs wireless plans will translate into meaningful demand.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

A steep selloff in Aehr shares is driving discussion as traders debate whether broader AI and semiconductor weakness, valuation concerns and bearish options flow point to more downside or an oversold setup ahead of earnings. Bulls are watching guidance, backlog and potential AI test-system orders, while skeptics question execution and the companys ability to justify its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IBM Stock Hits 52-Week High — Citi Raises Price Target To $375 On Quantum Push, Says Stock Is ‘Misunderstood’

Equity

Citi hikes IBM’s price target sharply after the company doubles down on a $10B quantum investment strategy.

IBM Stock Surges Premarket: Barclays’ Fresh Bull Call Highlights Quantum Potential, Retail Eyes $400 

On Monday, Barclays initiated coverage on the company’s shares with an ‘Overweight’ rating and a price target of $350, according to a report from Investing.com. 

Tradr Launches Leveraged ETFs on AMZN, AAOI, HL and IBM

Others

Investment Managers Series Trust II - Tradr 2X Long IBM Daily ETF

Bearish Sentiment

<ul class="summary-bullets"><li>Citi raises IBM price target to $375 from $285, maintaining a ‘Buy’ rating on the stock.</li><li>Analyst points to IBM’s planned $10B investment in quantum computing over five years.</li><li>IBM is seen as ‘underappreciated’ with potential exposure to a ~$850B federally supported quantum market.</li></ul>International Business Machines Corp. (IBM) ended Tuesday’s session at a 52-week high, boosted by upbeat sentiment and a higher price target from an analyst.IBM ended Tuesday’s session up 2.75%, before slipping in after-hours trading, down 0.67% at the time of writing.&nbsp;<h2 class="st-heading-2">Citi Raises IBM Price Target</h2>Citi turned bullish on the stock, raising its price target for IBM on Tuesday after the company outlined a major new investment push in quantum computing. The move reflects growing confidence in IBM’s long-term position in the emerging quantum technology market.Citi lifted its price target on IBM to $375 from $285 and maintained a ‘Buy’ rating on the stock, according to TheFly. This indicates an upside potential of about 14.7% from its previous close.&nbsp;The upgrade follows IBM’s plan to invest an additional $10 billion over five years to strengthen its quantum computing strategy and capabilities.According to the analyst, the timing and scale of the investment — coming shortly after IBM’s CHIPS Act grant win — signals strong confidence in its ability to compete in a quantum market estimated at roughly $850 billion and increasingly supported by federal initiatives. The analyst also described IBM as “underappreciated” and “misunderstood” by the broader market.<h2 class="st-heading-2">IBM Commits $10B To Expand Quantum Push</h2>IBM said it will invest over $10 billion in the next five years to advance its quantum computing efforts. The spending will be directed toward research and development, capital expenditures, manufacturing scale-up, ecosystem partnerships, and strategic acquisitions.The company said the investment is aimed at accelerating its roadmap, including its goal of delivering the world’s first large-scale, fault-tolerant quantum computer by 2029, while strengthening U.S.-based leadership in quantum technology.IBM also highlighted its existing position in the sector, saying it operates the largest fleet of quantum computers globally, with more than 90 systems deployed through cloud access and on-site installations. These systems are currently used by over 340 organizations across industry, academia, healthcare, and government.<h2 class="st-heading-2">IBM Stock: What Stocktwits Retail Sentiment Says</h2>On Stocktwits, retail sentiment around IBM was in the ‘extremely bullish’ territory, unchanged in the past 24 hours. Message volume was also ‘extremely high.’IBM’s message volume surged over 167% in the past seven days and more than 6,500% over 30 days, indicating a sharp rise in chatter around the stock.One bullish Stocktwits trader <a href="https://stocktwits.com/Jay_Trades_/message/655168883">said</a> IBM is in a “bump n run” setup and could break out toward $350+.<stembedurl>https://stocktwits.com/Jay_Trades_/message/655168883</stembedurl>Another retail trader on Stocktwits projected a much higher upside, <a href="https://stocktwits.com/BullishPullBacks/message/655171296">saying</a> IBM could rally toward $600.<stembedurl>https://stocktwits.com/BullishPullBacks/message/655171296</stembedurl><a href="https://stocktwits.com/symbol/IBM">IBM stock</a> has gained nearly 28% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Chip maker IBM logo is seen at the Mobile World Congress 2025 (MWC) at the Fira de Barcelona. (Photo by Davide Bonaldo/SOPA Images/LightRocket via Getty Images)

International Business Machines Corp. (IBM) ended Tuesday’s session at a 52-week high, boosted by upbeat sentiment and a higher price target from an analyst.

IBM Hits 52-Week High — Citi Sees Upside On $10B Quantum Investment Plan

International Business Machines Corp.

Tradr 2X Long IBM Daily ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$20.84
Prev Close	$20.91
Open	$20.94
Dividend Yield	N/A
50-Day Moving Average	$17.67
Beta	N/A
Avg. Volume	357,741.75
PE Ratio	N/A

52-Week High	$42.33
52-Week Low	$12.91
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

IBX Fundamentals